key: cord-0840762-n9jf47u8
authors: Chen, Chien-Chin; Chiang, Pei-Chun; Chen, Tsung-Hsien
title: The Biosafety and Risk Management in Preparation and Processing of Cerebrospinal Fluid and Other Neurological Specimens With Potential Coronavirus Infection
date: 2021-01-20
journal: Front Neurol
DOI: 10.3389/fneur.2020.613552
sha: 774aeb9177a55bebcc4990046d09be667385f855
doc_id: 840762
cord_uid: n9jf47u8

The recent outbreak of coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2, has become a global threat. Due to neurological manifestations presented throughout the coronavirus disease process, the potential involvement of COVID-19 in central nervous system has attracted considerable attention. Notably, the neurologic system could be widely affected, with various complications such as acute cerebrovascular events, encephalitis, Guillain-Barré syndrome, and acute necrotizing hemorrhagic encephalopathy. However, the risk assessment of exposure to potential biohazards in the context of the COVID-19 pandemic has not been clearly clarified regarding the sampling, preparation, and processing neurological specimens. Further risk managements and implantations are seldom discussed either. This article aims to provide current recommendations and evidence-based reviews on biosafety issues of preparation and processing of cerebrospinal fluid and neurological specimens with potential coronavirus infection from the bedside to the laboratory.

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has caused the coronavirus disease 2019 (COVID- 19) pandemic, an illness with the high transmissibility and a broad spectrum of clinical manifestation. As of December 15, 2020, the World Health Organization (WHO) reported more than 70 million cases and over 1.6 million deaths globally in the COVID-19 pandemic (1) . COVID-19 is the third epidemic of human coronavirus diseases after the severe acute respiratory syndrome (SARS) in November 2002, and the Middle East respiratory syndrome (MERS) in September 2012 (2) . In comparison with other epidemic coronaviruses, SARS-CoV-2 is less lethal but far more transmissible than MERS coronavirus (MERS-CoV) and SARS coronavirus (SAR-CoV) (3, 4) . It is believed that SARS-CoV-2 can spread by respiratory droplets, unprotected direct contact with patients, and touching contaminated objects (5, 6) . Since symptoms of COVID-19 can be in a wide variety of severity, medical professionals are in particular at risk of exposure to SARS-CoV-2 through close contact via respiratory droplets and contaminated surface and direct handling of contagious materials from patients with COVID-19 (7) . With regard to the safe collecting and handling clinical specimens in the pandemic, a few reports have emphasized the need for the worldwide standardization of biosafety protocols (5, 8, 9) . Notably, the neurological manifestation and morbidities of COVID-19 have been widely reported (10) (11) (12) (13) (14) (15) (16) . Mao et al. (15) reported that neurologic symptoms were present in 36.4% of all patients with COVID-19, especially more frequent in patients with severe illness. Moreover, in a patient with acute cerebellitis, the viral RNA of SARS-CoV-2 was detected in his oropharynx, nasopharynx, and cerebrospinal fluid (CSF) (17) . However, the biosafety and risk assessment in preparation and processing of CSF and other neurological specimens were seldom discussed. This mini-review aims to provide an integrative, evidence-based review to guide the preparation and processing of neurological specimens with potential coronavirus infection and therefore to prevent nosocomial infection.

Although COVID-19 primarily presents as a respiratory disease, SARS-CoV-2 affects multiple organs or systems, including the central nervous system (CNS), peripheral nervous system (PNS), and neuromuscular system (15, (18) (19) (20) . In a large case cohort of COVID-19, 24.8% had CNS symptoms (e.g., dizziness, headache, and impaired consciousness), 8.9% had PNS symptoms, and 10.7% had skeletal muscle injury (15) . In a nationwide surveillance of 125 patients with COVID-19 and neurological or psychiatric disease, 62% of them had a cerebrovascular event, while 31% of them presented with altered mental status (19) . Similarly, the epidemic of SARS was reported with various neurological complications including encephalopathy, seizures, stroke, cranial nerve palsies, peripheral neuropathy, and myopathy (20) (21) (22) (23) (24) . Also, patients with MERS were occasionally presented to have neurological symptoms and neuromuscular complications (24) (25) (26) (27) . The prevalence of CNS complications reached 0.04% for SARS and 0.20% for MERS, and besides the prevalence of PNS complications was 0.05% for SARS and 0.16% for MERS (14) .

Although the mechanism of CNS involvement of COVID-19 remains unclear, there is a three-step model which refers to viral neuroinvasion, CNS clearance, and immune response (28) . In the first stage, SARS-CoV-2 may enter the brain via the bloodstream and/or transcribriform route along the olfactory nerve, and the viral load in CSF should increase (28) . The respiratory symptoms are minimal in the early stage. With the interaction between the spike protein S1 of SARS-CoV-2 and the host angiotensin-converting enzyme 2 receptor (ACE2), SARS-CoV-2 may enter both glial and neuronal cells (29) . In some cases, the neuroinvasion may cause a direct neuronal damage and subsequently result in neurological symptoms. Moreover, the consumption and downregulation of ACE2 by SARS-CoV-2 virus may lead to imbalance of the renin angiotensin system resulting in endothelial dysfunction, vasoconstriction, and subsequently ischemic events (30) . In the second stage, SARS-CoV-2 may infect the brainstem affecting the respiratory drive. The viral load in respiratory secretions would increase predominantly, but the viral load in CSF significantly decreases. The CSF clearance of SARS-CoV-2 may greatly contribute to a low virus detection rate in CSF samples from patients with COVID-19 and CNS involvement. In the third stage, an immuno-mediated CNS damage may form, since SARS-CoV-2 can trigger the production of antibodies against glial cells, as a para-infective or postinfective phenomenon (28) . In consequence, the respiratory system would be severely affected and cause neurotoxic hypoxia with subsequent brain damage (28) .

With regard to neuromuscular involvement of SARS-CoV-2, myositis, acute myelitis, Guillain Barre syndrome, Miller Fisher syndrome, polyneuritis cranialis, oculomotor paralysis and Bell's Palsy have been discussed to be associated with COVID-19 (18, (30) (31) (32) (33) (34) . On electrodiagnostic testing, most of the abovementioned patients had demyelinating pattern, some had acute sensory motor axonal neuropathy, and few had acute motor axonal neuropathy (18) . In a patient with COVID-19 and myositis, the muscle biopsy revealed inflammatory infiltration around vessels and endomysial extension, regeneration of muscular fibers, and elevated HLA Class ABC expression (33) . The exact mechanism remains unknown, although a few hypothetic theories were proposed, including ACE2 mediated pathway, olfactory pathway, trans-synaptic pathway, and immune mediated pathway (18) . Since the muscle cells express ACE2, the direct invasion by the SARS-CoV-2 entering the muscle cells via the ACE2 may be possible (30) . In addition, cytokine storms in the advanced phase of COVID-19 could lead to immune-mediated muscle damages (30) .

Lumbar puncture (LP) is a medical procedure at the level of L2 to L5 vertebrae to collect CSF for examining infectious, inflammatory, and neoplastic diseases involving the CNS. In viral encephalitis, there is usually a mild to moderate CSF pleocytosis with predominant lymphocytes, normal glucose ratio, and slightly elevated protein (14, 35) . The standard of diagnosing a CNS viral infection is to demonstrate the virus in the CNS, either from culture or polymerase chain reaction (PCR) of brain tissue or CSF.

Muscle biopsy (MB) is important for the evaluation and diagnosis of patients who are suspected of having an underlying neuromuscular disorder (36) . With an open biopsy or needle biopsy technique under local anesthesia, bundles of skeletal muscles are taken for the required tests, including frozen sections for enzyme histochemistry, paraffin embedding for muscle fiber morphology and inflammatory patterns, electron microscopy for ultrastructural analysis, and biochemical testing for assessing storage and mitochondrial diseases (36) .

In the pandemic, to perform a LP or a MB might be at risk to expose coronaviruses, since direct contact or respiratory droplets might be infectious. Since both LP and MB are timeconsuming, the performer and all teammates would expose to 4 . Perform procedures in an adequately ventilated room with at least of 60 L/s/patient air flow. 5. Wear standard medical masks, eye protection (goggles) or facial protection (face shield), long-sleeved gowns, and gloves. 6. The process of contact with each patient, properly dispose of all PPEs and wastes and perform hand hygiene. 7. Clean and disinfect the surfaces that the patient was in contact with.

Precautions of transportation 1. Patient specimens from suspected or confirmed SARS-CoV-2 infection should be transported as UN3373, "Biological Substance Category B". 2. Deliver all specimens promptly by hand whenever possible. 3. Ensure that all personnel who transport specimens have received training in safe handling practices and spill decontamination procedures. 4. Timely notify the laboratory and correctly label the specimen with informative request forms.

Process samples 1. Diagnostic tests, such as cytology, biochemistry, and formalin-fixed paraffin sections, should be handled in a BSL-2 laboratory. 2. Wear and remove PPE properly, as determined by a detailed risk assessment, with hand hygiene. 3. Processing of all specimens before inactivation should take place in a validated biological safety cabinet or primary containment device. 4. All procedures should be performed in a manner that minimizes the generation of aerosols and droplets. 5. During processing, appropriate disinfectants with proven activity against coronaviruses should be used. (40). Although LP and MB are not aerosol-generating procedures, the neurological professionals should wear a medical mask, eye protection (goggles) or facial protection (face shield), a clean long-sleeved gown, and gloves (37) . After procedures, personal protective equipment and wastes should be properly disposed, and hand hygiene should be performed before and after contact with each patient. Lastly, it is important to clean and disinfect the surfaces that the patient was in contact with. With regard to the transportation, CSF or muscle for virus detection can be shipped at 2-8 • C and delivered promptly to the laboratory (41) . Notably, patient specimens from suspected or confirmed SARS-CoV-2 infection should be transported as UN3373, "Biological Substance Category B" (42, 43) . All the biosafety recommendations are summarized in Table 1 .

Since all specimens collected for laboratory investigations should be considered potentially infectious, all procedures must be performed according to risk assessment and strategies for biosafety (42, 43) . Before inactivation of all specimens, the initial processing should be performed in a validated biological safety cabinet or primary containment device (42) . In addition to detecting viruses by sequencing or PCR, all diagnostic laboratory works for neurological specimens, including biochemistry, cytology, and special stains should be performedat a facility using procedures equivalent to Biosafety Level 2 (BSL-2) (42, 43) . In the light of inactivation of coronaviruses, fixatives with ethanol concentrations of 78%-95% for at least 30 s could inactivate SARS-CoV, and either 10% formalin or 4% paraformaldehyde for at least 30 min would efficiently inactivate MERS-CoV-infected cells (9) . Alcohol fixed preparation also lyses red blood cells, reducing the risk of viremia. The abovementioned fixations are the reasons why specimens with Papanicolaou staining or formalin fixation can be taken as inactivated (9) . Moreover, the external lysis buffer of common RNA extraction kits for viral detection is effective to inactivate SARS-CoV-2 without heat or other additional methods (42) .

Currently, the identification of viral RNA through nucleic acid amplification technologies, such as reverse-transcription polymerase chain reaction (RT-PCR) in a patient's biological samples, remains the gold standard for identifying infections with coronaviruses. Notably, SARS-CoV was detected in CSF by RT-PCR in two cases of encephalopathy (44, 45) and was cultured from brain tissues of an autopsy case (46) . In the COVID-19 pandemic, although the neurological manifestations were not uncommon, SARS-CoV-2 RNA was rarely detected in CSF by RT-PCR (Table 2 ) (17, (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) . And, to the best of our knowledge, there is no MB specimen demonstrating the evidence of SARS-CoV-2 infection via culture or RT-PCR. Based on the relative frequencies of detectable SARS-CoV-2 RNA in different samples from published reports, Chen and Chi (5) suggested to categorize the cytological and pathological samples into the high risk, intermediate risk, and low risk groups. Accordingly, CSF and MB specimens can be categorized into the low risk group with limited evidence of SARS-CoV-2 RNA detection and should subsequently follow the principles of good microbiological practices and procedures to be handled (5) .

Although the presence of viral RNA is not equivalent to live infectious viruses, RT-PCR is an important method to identify infectious agents (66) .

With the growing number of confirmed COVID-19 cases, it is essential that the neurological experts and clinical laboratories implement clinical triage, drastic measures, and appropriate procedures and facilities for ensuring the safety and interests of valuable healthcare workers in times of the pandemic. The lessons learned from SARS and MERS could give us more insights to conduct efficient preventive measures in healthcare settings. Although LP and MB are important diagnostic procedures for CNS and neuromuscular diseases, neurological practitioners must be well-prepared and avoid of non-emergent procedures to prevent potential exposures to COVID-19. The collection, transportation, and processing of neurological specimens should warrant the use of WHO guidelines, academic recommendations, and BSL-2 procedures. Herein, although the biological safety and security issues were rarely discussed in neurology, we hope that both neurologists and laboratory professionals can benefit from this integrative mini-review in dealing with the COVID-19 crisis.

C-CC: study concept and design, acquisition of data, manuscript writing, critical revision of the manuscript for important intellectual content, and study supervision. P-CC: acquisition of data, analysis and interpretation, manuscript writing, and critical revision of the manuscript for important intellectual content. T-HC: critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Weekly Epidemiological Update-15

Three emerging coronaviruses in two decades

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

COVID-19, SARS and MERS: are they closely related?

Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID-19) infection: perspectives from Taiwan

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Protecting Chinese healthcare workers while combating the 2019 novel coronavirus

Impact of the COVID-19 pandemic on cytology practice: an international survey in the Asia-Pacific region

Reply to Rapid on-site evaluation and the COVID-19 pandemic

The neurology of COVID-19 revisited: a proposal from the environmental neurology specialty group of the world federation of neurology to implement international neurological registries

Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management

Lifting the mask on neurological manifestations of COVID-19

Effects of COVID-19 on the nervous system

Neurological associations of COVID-19

Neurological manifestations in critically ill patients with COVID-19: a retrospective study

A first case of acute cerebellitis associated with Coronavirus Disease (COVID-19): a case report and literature review

Neuromuscular complications with SARS-COV-2 infection: a review

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Nervous system involvement after infection with COVID-19 and other coronaviruses

Neurological manifestations in severe acute respiratory syndrome

Neuromuscular disorders in severe acute respiratory syndrome

Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis

SARS and MERS: recent insights into emerging coronaviruses

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

Neurological complications of middle east respiratory syndrome coronavirus: a report of two cases and review of the literature

Neurological complications during treatment of Middle East respiratory syndrome

Three-steps" infection model and CSF diagnostic implication

SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms

Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic

Acute transverse myelitis in COVID-19 infection

Acute transverse myelitis after COVID-19 pneumonia

COVID-19-associated myositis with severe proximal and bulbar weakness

Neuromuscular presentations in patients with COVID-19

Viral encephalitis: a clinician's guide

Muscle biopsy evaluation in neuromuscular disorders

Infection Prevention and Control During Health Care When Novel Coronavirus (nCoV) Infection Is Suspected. Interim Guidance

Neurosurgical practice during coronavirus disease 2019 (COVID-19) pandemic

Society of neurointerventional surgery recommendations for the care of emergent neurointerventional patients in the setting of COVID

Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents

Laboratory Testing for 2019 Novel Coronavirus (2019-nCoV) in Suspected Human Cases. Interim Guidance

Laboratory Biosafety Guidance Related to Coronavirus Disease (COVID-19). Interim Guidance

Available online at

Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome

Possible central nervous system infection by SARS coronavirus

Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Headache and impaired consciousness level associated with SARS-CoV-2 in CSF: a case report

First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease

COVID-19-associated meningoencephalitis treated with intravenous immunoglobulin

First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder

Encephalitis associated with the SARS-CoV-2 virus: a case report

Novel coronavirus and the central nervous system

Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke

Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis

Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease

Covid-19-related encephalopathy: a case series with brain FDG-PET/CT findings

Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms

Immune-mediated neurological syndromes in SARS-CoV-2-infected patients

Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic

Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA levels in the cerebrospinal fluid

Cerebrospinal analysis in patients with COVID-19

CSF biomarkers in patients with COVID-19 and neurological symptoms: a case series

COVID-19 meningitis without pulmonary involvement with positive cerebrospinal fluid PCR

Recommendations for cerebrospinal fluid analysis

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2021 Chen, Chiang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.